中慧生物-B(02627.HK)上半年亏损1.22亿元 营收同比增长919.25%

Group 1 - The core viewpoint of the article highlights that Zhonghui Biotech-B (02627.HK) reported a significant revenue increase of 919.25% year-on-year, amounting to RMB 71.123 million for the six months ending June 30, 2025 [1][2] - The company incurred a loss of RMB 122 million during the same period, which is an improvement from a loss of RMB 156 million in the previous year [1][2] - The revenue growth is attributed to the increasing sales of the quadrivalent influenza virus subunit vaccine and adjustments made to calibrate the estimated returns for 2024 sales [1] Group 2 - Zhonghui Biotech-B has received IND approval for its respiratory syncytial virus vaccine (CHO cell) from both China's CDE and the US FDA [2]